Harvard MedTech has announced data shows that its Vx Therapy reduces cost and duration of treatment, risk of long-term disability, and avoids the use of prescription drugs.

Also, the treatment would facilitate a significant return-on-investment (ROI), achieving ROI levels as high as 35:1, in few documented cases, said the company.

Vx Therapy model integrates digital technologies with behavioural health interventions, in a virtual application, and can be used at the patient’s home.

It enables patients to leverage virtual reality technology to achieve positive, engaging experiences and reduction in the sensation of pain while the brain builds new neural pathways.

Harvard MedTech chief medical officer Gerry Stanley said: “Pain is more than a biologic response, so our solution takes into account the psychosocial elements of trauma and the fact that every person suffers differently.

“We leverage the latest science on how the brain works to re-program itself to reduce the sensation of pain and anxiety by using virtual reality technology and customised behavioural interventions, guided by artificial intelligence.

“With this approach, patients break the cycle of chronic pain and the debilitating psychosocial disorders that accompany trauma.”

In a recent study, Harvard MedTech has enrolled 36 participants with chronic debilitating pain from workplace injuries, in its Vx Therapy programme.

The study results revealed that wearing headsets resulted in a reduction in pain levels by an average of 40%, and patients experienced 2.8 hours of relief post-treatment, which is legacy pain relief.

Medication usage tracking revealed that 69% of patients reported either a decrease or a complete cessation of opiate use, over the course of the programme.

Vx Therapy is currently being used by major medical institutions and workers’ compensation organisations to manage care for patients who are suffering from chronic pain, and trauma.

The virtual engagement is said to drive high compliance, patient satisfaction and optimal outcomes, and allows the solution to be affordable and scalable at a population health level.

Stanley added: “We’ve demonstrated that Vx Therapy reduces the risk of higher cost workers’ compensation claims, the likelihood of long-term claims due to pain and psychosocial problems, and the cost and risk of addiction to prescription medications or illegal drugs to control pain and mood.

“Simply put, this breakthrough approach harnesses the power of the brain to help restore a sense of normalcy to patients who have suffered a trauma.”